Drug intelligence / Profile preview

BI0107 ADC

Development stage: Preclinical
Lead developer: Protheragen
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BI0107 ADC is a preclinical-stage antibody-drug conjugate (ADC) being developed by Protheragen for the treatment of acute myeloid leukemia (AML). The drug targets C-type lectin domain family 12 member A (CLEC12A), also known as CLL-1, which is a cell surface marker highly expressed on AML blasts and leukemic stem cells but absent on normal hematopoietic stem cells. By specifically binding to CLEC12A, BI0107 ADC is designed to deliver a potent cytotoxic payload directly into the malignant cells, thereby inducing apoptosis while minimizing damage to healthy bone marrow components.

Targets

CLEC12A

Beyond the preview

Go deeper on BI0107 ADC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI0107 ADC.

Explore the full profile